Molecular Devices Will 'Reassess' Product Lines Following Cut in Third-Quarter Revenue Guidance | GenomeWeb
Molecular Devices, which cut its third-quarter revenue outlook by as much as 12 percent last week, may have to reassess certain product lines if the flat sales continue, President and CEO Joseph Keegan told investors at a recent conference.
Keegan, who refused to blame any one product line or the company’s overall sales and marketing force for the revenue shortfall, also said the company would focus on increasing the level of specialization of a sales and marketing team that “might be at capacity.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.